select a format

Single User License
USD 2000 INR 128320
Site License
USD 4000 INR 256640
Corporate User License
USD 6000 INR 384960

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Adenocarcinoma of the Gastroesophageal Junction-Pipeline Review, H2 2015

Adenocarcinoma of the Gastroesophageal Junction-Pipeline Review, H2 2015


  • Products Id :- GMDHC7228IDB
  • |
  • Pages: 219
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Adenocarcinoma of the Gastroesophageal Junction-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Adenocarcinoma Of The Gastroesophageal Junction-Pipeline Review, H2 2015', provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Adenocarcinoma Of The Gastroesophageal Junction and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Adenocarcinoma Of The Gastroesophageal Junction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Adenocarcinoma Of The Gastroesophageal Junction pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Adenocarcinoma of the Gastroesophageal Junction Overview 10

Therapeutics Development 11

Pipeline Products for Adenocarcinoma of the Gastroesophageal Junction-Overview 11

Adenocarcinoma of the Gastroesophageal Junction-Therapeutics under Development by Companies 12

Adenocarcinoma of the Gastroesophageal Junction-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Adenocarcinoma of the Gastroesophageal Junction-Products under Development by Companies 18

Adenocarcinoma of the Gastroesophageal Junction-Companies Involved in Therapeutics Development 21

AB Science SA 21

Amgen Inc. 22

ArQule, Inc. 23

AstraZeneca Plc 24

Boehringer Ingelheim GmbH 25

Boston Biomedical, Inc. 26

Bristol-Myers Squibb Company 27

Cerulean Pharma, Inc. 28

Daiichi Sankyo Company, Limited 29

Dr. Reddy's Laboratories Limited 30

Eli Lilly and Company 31

Epirus Biopharmaceuticals, Inc. 32

F. Hoffmann-La Roche Ltd. 33

Ganymed Pharmaceuticals AG 34

Genentech, Inc. 35

Gilead Sciences, Inc. 36

Imugene Limited 37

Johnson & Johnson 38

Mebiopharm Co., Ltd. 39

MedImmune, LLC 40

Merck & Co., Inc. 41

Merck KGaA 42

Millennium Pharmaceuticals, Inc. 43

Novartis AG 44

Oncobiologics, Inc. 45

Otsuka Holdings Co., Ltd. 46

Panacea Biotec Limited 47

Sanofi 48

Adenocarcinoma of the Gastroesophageal Junction-Therapeutics Assessment 49

Assessment by Monotherapy Products 49

Assessment by Combination Products 50

Assessment by Target 51

Assessment by Mechanism of Action 54

Assessment by Route of Administration 56

Assessment by Molecule Type 58

Drug Profiles 60

(tipiracil hydrochloride + trifluridine)-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

alpelisib-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

AMG-337-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

avelumab-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

AZD-4547-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

BI-853520-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

cabazitaxel-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

CRLX-101-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

DS-8201a-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

durvalumab + tremelimumab-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

emibetuzumab-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

erismodegib-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

GS-5745-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Her-VAXX-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

IMAB-362-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

indusatumab vedotin-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

ipatasertib-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

ipilimumab-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

JNJ-42756493-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

masitinib-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

MBP-426-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

napabucasin-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

panitumumab-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

PDR-001-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

pembrolizumab-Drug Profile 111

Product Description 111

Mechanism of Action 111

R&D Progress 111

pertuzumab-Drug Profile 120

Product Description 120

Mechanism of Action 120

R&D Progress 120

ramucirumab-Drug Profile 124

Product Description 124

Mechanism of Action 124

R&D Progress 124

SAR-408701-Drug Profile 130

Product Description 130

Mechanism of Action 130

R&D Progress 130

solitomab-Drug Profile 131

Product Description 131

Mechanism of Action 131

R&D Progress 131

tivantinib-Drug Profile 132

Product Description 132

Mechanism of Action 132

R&D Progress 132

trastuzumab biosimilar-Drug Profile 134

Product Description 134

Mechanism of Action 134

R&D Progress 134

trastuzumab biosimilar-Drug Profile 135

Product Description 135

Mechanism of Action 135

R&D Progress 135

trastuzumab biosimilar-Drug Profile 136

Product Description 136

Mechanism of Action 136

R&D Progress 136

trastuzumab biosimilar-Drug Profile 137

Product Description 137

Mechanism of Action 137

R&D Progress 137

trastuzumab biosimilar-Drug Profile 138

Product Description 138

Mechanism of Action 138

R&D Progress 138

trastuzumab emtansine-Drug Profile 139

Product Description 139

Mechanism of Action 139

R&D Progress 139

Adenocarcinoma of the Gastroesophageal Junction-Recent Pipeline Updates 143

Adenocarcinoma of the Gastroesophageal Junction-Dormant Projects 209

Adenocarcinoma of the Gastroesophageal Junction-Discontinued Products 211

Adenocarcinoma Of The Gastroesophageal Junction-Product Development Milestones 212

Featured News & Press Releases 212

Jul 01, 2015: Phase 1b/2 Gastric Cancer Trial on Track with Contract Research Organisation Appointed to Conduct Trial 212

Jun 01, 2015: Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitor BBI608 in Multiple Cancer Types 212

May 18, 2015: AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting 214

Jul 22, 2014: Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer 216

Appendix 218

Methodology 218

Coverage 218

Secondary Research 218

Primary Research 218

Expert Panel Validation 218

Contact Us 218

Disclaimer 219

List of Tables

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Development by Companies, H2 2015 (Contd...1) 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Development by Companies, H2 2015 (Contd...1) 19

Products under Development by Companies, H2 2015 (Contd...2) 20

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by AB Science SA, H2 2015 21

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Amgen Inc., H2 2015 22

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by ArQule, Inc., H2 2015 23

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by AstraZeneca Plc, H2 2015 24

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Boehringer Ingelheim GmbH, H2 2015 25

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Boston Biomedical, Inc., H2 2015 26

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Bristol-Myers Squibb Company, H2 2015 27

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Cerulean Pharma, Inc., H2 2015 28

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 29

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 30

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Eli Lilly and Company, H2 2015 31

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 32

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 33

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Ganymed Pharmaceuticals AG, H2 2015 34

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Genentech, Inc., H2 2015 35

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Gilead Sciences, Inc., H2 2015 36

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Imugene Limited, H2 2015 37

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Johnson & Johnson, H2 2015 38

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Mebiopharm Co., Ltd., H2 2015 39

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by MedImmune, LLC, H2 2015 40

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Merck & Co., Inc., H2 2015 41

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Merck KGaA, H2 2015 42

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 43

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Novartis AG, H2 2015 44

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Oncobiologics, Inc., H2 2015 45

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Otsuka Holdings Co., Ltd., H2 2015 46

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Panacea Biotec Limited, H2 2015 47

Adenocarcinoma Of The Gastroesophageal Junction-Pipeline by Sanofi, H2 2015 48

Assessment by Monotherapy Products, H2 2015 49

Assessment by Combination Products, H2 2015 50

Number of Products by Stage and Target, H2 2015 52

Number of Products by Stage and Mechanism of Action, H2 2015 55

Number of Products by Stage and Route of Administration, H2 2015 57

Number of Products by Stage and Molecule Type, H2 2015 59

Adenocarcinoma Of The Gastroesophageal Junction Therapeutics-Recent Pipeline Updates, H2 2015 143

Adenocarcinoma Of The Gastroesophageal Junction-Dormant Projects, H2 2015 209

Adenocarcinoma Of The Gastroesophageal Junction-Dormant Projects (Contd...1), H2 2015 210

Adenocarcinoma Of The Gastroesophageal Junction-Discontinued Products, H2 2015 211

List of Figures

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 16

Assessment by Monotherapy Products, H2 2015 49

Assessment by Combination Products, H2 2015 50

Number of Products by Top 10 Targets, H2 2015 51

Number of Products by Stage and Top 10 Targets, H2 2015 51

Number of Products by Top 10 Mechanism of Actions, H2 2015 54

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 54

Number of Products by Routes of Administration, H2 2015 56

Number of Products by Stage and Routes of Administration, H2 2015 56

Number of Products by Top 10 Molecule Types, H2 2015 58

Number of Products by Stage and Top 10 Molecule Types, H2 2015 58

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science SA

Amgen Inc.

ArQule, Inc.

AstraZeneca Plc

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Cerulean Pharma, Inc.

Daiichi Sankyo Company, Limited

Dr. Reddy's Laboratories Limited

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

Ganymed Pharmaceuticals AG

Genentech, Inc.

Gilead Sciences, Inc.

Imugene Limited

Johnson & Johnson

Mebiopharm Co., Ltd.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

Novartis AG

Oncobiologics, Inc.

Otsuka Holdings Co., Ltd.

Panacea Biotec Limited

Sanofi

Adenocarcinoma Of The Gastroesophageal Junction Therapeutic Products under Development, Key Players in Adenocarcinoma Of The Gastroesophageal Junction Therapeutics, Adenocarcinoma Of The Gastroesophageal Junction Pipeline Overview, Adenocarcinoma Of The Gastroesophageal Junction Pipeline, Adenocarcinoma Of The Gastroesophageal Junction Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com